secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001193125-23-025588
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus acquires Cerveau Technologies, adding Alzheimer's Tau PET imaging agent MK-6240
--------------------------------------------------------------------------------

- Acquired Cerveau Technologies, gaining MK-6240, an F18-labeled PET imaging agent targeting Tau tangles in Alzheimer's disease.
- MK-6240 is currently used in over 60 academic and industry clinical trials by more than 16 pharmaceutical companies.
- Terms include upfront payment plus development and commercial milestone payments, with double-digit royalties on research revenue and commercial sales.
- Transaction structured as a stock purchase; seller to provide transition and clinical development services post-closing.
- Lantheus expects to expand its radiopharmaceutical diagnostic imaging pipeline into Alzheimer's disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312523025588/0001193125-23-025588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312523025588/d462129d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-025588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer